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ABSTRACT 
Objectives: There is an on-going debate about excluding patient global assessment (PGA) from 
composite and Boolean-based definitions of rheumatoid arthritis (RA) remission. This study aimed 
at i) determining the influence of PGA on RA disease states, exploring differences across countries, 
and ii) understanding the association between PGA, measures of disease impact (symptoms) and 
markers of disease activity (inflammation). 
Methods: Cross-sectional data from the METEOR international database were used. We calculated 
the proportion of patients failing ACR/EULAR Boolean-based remission (4v-remission) solely due to 
PGA (PGA-near-remission) in the overall sample and in the most representative countries (i.e. with 
over 3,000 patients in the database). Multivariable linear regression models were used to identify 
the main determinants of PGA, grouped in (predominantly) inflammatory (28-tender and 28-swollen 
joint counts and C-reactive protein) and disease impact factors (pain and function).  
Results: This study included 27,768 patients. Excluding PGA from the Boolean-based definition 
(3v-remission) increased remission rate from 5.8% to 15.8%. The rate of PGA-near-remission varied 
considerably between countries, from 1.7% in India to 17.9% in Portugal. One third of patients in 
PGA-near-remission scored PGA>4/10. Pain and function were the main correlates of PGA, with 
inflammation-related variables contributing less to the model (R2=0.57).  
Conclusions: PGA is moderately related to joint inflammation overall, but only weekly so in low 
levels of disease activity. A considerable proportion of patients otherwise in biological remission still 
perceive high PGA, putting them at risk of excessive immunosuppressive treatment.  
 
Keywords: Arthritis, Rheumatoid; Patient Global Assessment; Patient reported outcomes; 
Disease activity; Remission 
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Significance and Innovation 
 
 Among 27,799 patients with rheumatoid arthritis from a large number of countries, 10% failed 
to reach ACR/EULAR Boolean-based remission only due to a PGA>1 and among these, 
around 1/3 scored PGA>4 (0-10 scale).  
 PGA showed a moderate to poor relationship with disease activity, especially at levels close 
to define treatment targets. 
 The inclusion of PGA in definitions of remission may lead to overtreatment with 
immunosuppressive drugs.  
 The patient’s perspective remains essential to patient care. However, a separation between 
"inflammatory" and disease impact targets will probably improve safety and outcomes from 
the patients’ perspective. 
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INTRODUCTION 
Remission is now the target of treatment in rheumatoid arthritis (RA) (1, 2). However, the percentage 
of patients achieving remission is strongly influenced by the remission definition used (3), and there 
is currently no consensus on which definition is the most appropriate to support a Treat-to-Target 
(T2T) approach (4). The most authoritative definition, adopted conjunctly by the American College 
of Rheumatology (ACR) and the European League Against Rheumatism (EULAR)(5), provides two 
alternative definitions: (i) either a Boolean-based definition [28-swollen joint count (SJC28), 28-
tender joint count (TJC28), C-reactive protein (CRP, mg/dl), and patient global assessment (PGA, 
0-10cm scale) all ≤1], or (ii) a Simplified Disease Activity Index (SDAI) ≤3.3. The SDAI results from 
the simple sum of the four Boolean components and the Physician Global Assessment (PhGA, 0-
10cm scale). Two other commonly used definitions are based on 28-joint count Disease Activity 
Score (DAS28), either with 4 or 3 variables (i.e. with or without PGA), (6) or the Clinical Disease 
Activity Index (CDAI, same formula as SDAI, but without CRP) (7, 8).  
PGA is included in all these definitions, except in DAS28(3v), but there is an on-going debate 
regarding whether it should remain in the definition. Its inclusion has been justified because PGA 
tends to accompany disease activity (inflammation control) in clinical trials of RA (5) and because it 
conveys the patient perspective, which is obviously core to the objectives of treatment (9). However, 
a growing concern has emerged as to whether PGA reflects disease activity at the biological 
inflammatory process close enough to make it an appropriate instrument to define target for 
immunosuppressive therapies (10-12), namely in long-term follow-up and in low-disease activity 
populations followed in clinic al practice. Support for this has been demonstrated by low correlation 
of PGA with joint counts and acute phase reactants (10, 13, 14), and PGA being unrelated to 
structural damage or other important outcomes (15, 16) that treat to target aims to prevent. PGA is 
highly affected by comorbidities and by other musculoskeletal and psychological conditions (e.g. 
osteoarthritis, fibromyalgia, depression) that cannot be improved by therapies targeting the 
inflammatory process, which makes it inappropriate to guide the readjustment of such therapies (11, 
17, 18). Additionally, concerns have been raised regarding the variety of formulations used to ask 
this question (18), which have been shown to influence remission rates by 4.7% to 6.3% (19). 
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Patient's health literacy also affects the validity and reliability of PGA: about 40% of patients find the 
concept of PGA confusing and difficult to mark (20). 
The importance of understanding how PGA influences disease activity classification became 
especially important with the new ACR/EULAR remission criteria, given that a PGA score >1 
excludes remission, even if all the other three criteria are ≤1 (a condition referred to as PGA-near-
remission state). Several independent studies have shown that 14% to 38% patients with RA, in 
different settings, are in PGA-near-remission (10, 21-25), although these proportions need to be 
confirmed in larger international samples. The main issue is that following current treatment 
recommendations (1, 2) this state of PGA-near-remission would justify intensification of 
immunosuppressive treatment, after considering "other patient factors, such as progression of 
structural damage, comorbidities and safety issues"(1), or "patient's individual circumstances"(2). It 
has been argued that treatment decisions are more nuanced and most rheumatologists would be 
unlikely to base a treatment escalation decision on the value of the PGA alone (26). The question 
remains: if it is acceptable that rheumatologists ignore PGA for treatment decisions, why should it 
be kept in target definitions? Other researchers have proposed the increase of the cut-off point of 
PGA to around 2.5 or 3 cm (27, 28), but this does not solve the problems of validity and reliability 
mentioned above.  
Members of our group (10, 29) have proposed the dual-target concept involving concomitant and 
obligatory use of two different targets: a measure of inflammatory disease activity (biological 
remission or 3v-remission) and a measure of patient-reported impact of the disease (symptom 
remission). The latter should be based on patient reported outcomes (PROs) that are better than 
PGA at discriminating disease impact, thus help to guide adjunctive therapy (10, 29). This has 
ignited controversy (12, 26). The concepts being addressed are of crucial importance in defining 
management strategies, justifying the need of further studies to enlighten the on-going debate (30). 
METEOR, a large international longitudinal database, reflecting current clinical practice, provides a 
valuable opportunity to take into account the variability of clinical settings of care provision, including 
differences in cultural background, as well as treatment accessibility and standards. 
The objectives of the present study were (i) to determine the influence of PGA on the classification 
of patients according to disease activity states, particularly remission, and explore differences across 
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countries (ii) to explore the range of PGA values among patients in remission by DAS28 and in PGA-
near-remission, and (iii) to determine the associations of PGA with markers of inflammation and of 
impact of disease.   
 
PATIENTS AND METHODS 
Patients and study design 
This study used data from the "Measurement of Efficacy of Treatment in the Era of Outcome in 
Rheumatology" (METEOR) database, an on-going prospective international register of patients with 
RA founded in 2006 (31, 32). The METEOR is a free web-based tool available worldwide, with >33 
countries, >45.000 patients, and >270.000 visits, corresponding to a mean (SD) of 3.1 (3.1) person-
years of follow-up. Data regarding patient’s socio-demographics, diagnosis, treatment and follow-
up, according to usual care, are collected anonymously in a central database. Data can also be 
uploaded from local electronic health record systems or registries, which is the case in, among 
others, the Netherlands, Portugal and India (31, 32). All data in METEOR are fully anonymised and 
all follow-up visits, measurements and medication were based on daily clinical practice, therefore, 
medical ethics approval was not required. 
For this study, the patients’ first visit registered in METEOR, from adult patients, with no missing 
data in the variables used to determine ACR/EULAR Boolean-based remission status were selected. 
The database included visits from June 1985 till December 2017. 
 
Assessments 
PGA of "the current activity of the disease" was measured on 0-10 cm visual analogue scale (VAS), 
with 0 (not active at all) and 10 (extremely active) as anchors. Although the meaning of the question 
was the same, the exact formulation of the question varied across countries. 
Other PROs assessed were pain (VAS, 0-10cm) and physical function, measured by the Health 
Assessment Questionnaire Disability Index (HAQ-DI)(33). The following clinical and demographic 
parameters were also considered for sample characterization: gender, age at visit, disease duration 
  7 
since diagnosis, Gross Domestic Product per capita (GDP) of the Country, presence of erosions, 
and current treatment with biological (bDMARDs) or targeted synthetic (tsDMARDs). 
 
Definitions of remission  
The ACR/EULAR Boolean-based definition (5) was adapted to classify patients in three main 
remission states: i) Boolean-based remission (TJC28, SJC28, CRP mg/dl, and PGA, all ≤1), also 
designated in this study as 4v-remission, ii) PGA-near-remission (TJC28, SJC28, CRP mg/dl all ≤1 
and only PGA>1) (10), and iii) Non-remission (if two or more criteria are >1). The proposed binary 
definition of "3v-remission" (same criteria as 4v-remission but excluding PGA) (10, 16) was also 
tested. Naturally, 3v-remission = 4v-remission + 4v-PGA-near-remission. The proportions of patients 
that failed Boolean remission due to a single criterion, other than PGA, were also calculated (21). 
An even stricter 3v-Boolean-based criteria, defined by the authors as SJC28=0, TJC28=0, and CRP 
(mg/dl) ≤0.5 ("Strict 3v-remission") was used, in exploratory analyses, to asses the percentage of 
patients scoring PGA≤1 under these circumstances. The SDAI (≤3.3) and the CDAI (≤2.8) (7, 8) 
remission definitions were also used to establish their prevalence among patients in PGA-near-
remission state. 
Regarding DAS28, remission states were assessed with the DAS28-CRP (34), because it was 
available in more patients than DAS28-ESR and because the other definitions of remission also 
include CRP.  We used the most recently proposed cut-offs (35). 
 
Statistical analyses 
Data were analysed using IBM® SPSS® Statistics, version 20.0 software (IBM, Armonk, NY, USA). 
Quantitative data were expressed as means (standard deviation, SD) and categorical data as 
frequencies and percentages. The influence of PGA in the rates of remission according to the 
various definitions was assessed in two ways: (i) comparing the remission rates according to 
DAS28-CRP(4v) versus DAS28-CRP(3v), and (ii) determining the proportion of patients in PGA-
near-remission (Boolean definition). Secondary analyses included determining: (i) the distribution of 
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PGA values from patients fulfilling DAS28-CRP remission, PGA-near-remission, and "Strict 3v-
remission", and (ii) the proportion of patients in PGA-near-remission that are also in SDAI and CDAI 
remission states. 
Pearson’s correlation coefficients between PGA, and SJC28, TJC28, CRP, DAS28-CRP3v, pain 
scores and function (HAQ-DI) were calculated, and categorized as high, r≥0.60; moderate, r=0.40-
.59 and low r<0.40 (36). Correlations with DAS28-CRP(3v) were separately assessed for patients 
in remission/low disease activity, as this is the subgroup where the use of PGA in managing 
treatment according to current recommendations has the greatest impact. Differences between the 
most represented countries (n>3000 patients) in the database were explored. Multivariable linear 
regression models ("Enter" Method, with all variables) with PGA as dependent variable were used 
to analyse its main determinants from two main domains: (predominantly) inflammatory (SJC28, 
TJC28, CRP) and patient-reported impact measures (Pain and Function).  
 
RESULTS 
Patient characteristics 
Among the 43,341 patients (264,920 visits) available in the database, only 27,768 patients/visits 
were included (i.e. the first among 109,556 recorded visits without missing data in the four Boolean 
criteria). Table 1 presents the patient characteristics, representing 32 countries (Supplementary 
Table S1). Mean (SD) disease duration since diagnosis was 4.3 (7.3) years, 83.4% diagnosed from 
the year 2000 onwards and 23.2% of the patients were currently on bDMARDS. The mean DAS28-
CRP(3v) was 4.2 (2.6) and the mean PGA was 4.9 (2.6).  
 
Influence of PGA in remission states 
The overall remission rate according to the ACR/EULAR Boolean-based definition was 5.8%. An 
additional 10.0% of patients failed to achieve remission solely because of PGA (“PGA-near-
remission” patients). The rate of PGA-near-remission across countries was 1.7% in India, 7.1% in 
Italy, 13.7% in the Netherlands, 15.6% in other countries, and 17.9% in Portugal (Table 2). 
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Altogether, the remission rate would increase from 5.8 to 15.8% if the Boolean 3v-remission was 
used instead of the 4v, i.e., if PGA was excluded from the definition. The maximum difference was 
observed in Portugal: from 9.0 to 26.9% (Table 2). PGA was clearly the major obstacle to 4v-
remission, justifying 79.7% of all the cases of near-remission in the overall sample.   
The inclusion of PGA in the DAS28-CRP formula led to a drop of 1.8% in the remission rate in the 
overall sample (16.7 versus 14.9%) (Table 2), a difference that varied from 0.5% in India to 3.2% in 
Portugal. If the low disease activity state was considered the target, the decrease in rate imposed 
by PGA was 2.9% in the overall sample (24.8 versus 21.9%), reaching a maximum difference of 
4.3% in Portugal.  
 
PGA values among patients in (near-)remission and "strict 3v-remission" 
Figure 1 presents the distribution of PGA in these patients with low or null signs of inflammation. It 
shows that a considerable proportion report a high PGA: 37.4% of patients in ACR/EULAR Boolean 
PGA-near-remission had a PGA >4/10. The mean (SD) PGA in these patients was 3.9 (2.0) for the 
overall sample, with similar values in the different countries (Table 3). Among patients in PGA-near-
remission, 13.1% and 9.8% were in SDAI and CDAI remission states, respectively (data not shown). 
Considering only the patients with SJC28=0, TCJ28=0, and CRP (mg/dl) ≤0.5, herein defined as in 
“strict 3v-remission” (n=2395), only 43.5% had a PGA≤1 and 20.0% had a PGA>4. 
The mean (SD) PGA among patients in DAS28CRP3v remission was 2.5cm (2.3), while for patients 
in low disease activity state was 3.7cm (2.4) (Table 3).  
 
PGA associations with inflammation-related variables and with disease impact measures 
In the overall sample, the correlation of PGA was strong with Pain (rp=0.75), moderate with function 
(rp=0.52) and DAS28-CRP(3v) (rp=0.51), and weak with the individual components of DAS28-
CRP(3v) (all p<0.001) (Table 4). The correlation between DAS28-CRP(3v) and PGA in patients in 
remission and in low disease activity was 0.25. These correlations varied considerably across 
countries, with patients from the Netherlands and India presenting the lowest correlations between 
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PGA and inflammatory and patient-reported measures. There was a clear relationship between 
DAS28 and PGA: the mean value of PGA in patients with high disease activity, as defined by DAS28, 
was 6.2 as compared to 2.5 for patients in remission (Table 3). 
In multivariable analysis, pain (βstandardized=0.591) and function (βstandardized=0.156) were the main 
explanatory factors of PGA. To a smaller extent, TJC28 (βstandardized=0.111), CRP (βstandardized=0.034), 
and SJC28 (βstandardized=0.030) were also statistically significant in the model, which explains 57.3% 
of PGA's variance (p<0.001) (Table 5).  
 
DISCUSSION 
This study assessed the influence of PGA on the classification of patients’ remission status 
according to two definitions, using a large international clinical practice cohort, and tested its 
associations with factors predominantly associated with "inflammatory activity" or with impact of 
disease.  
Overall, the ACR/EULAR Boolean-based (4v-) remission was achieved by 5.8% of the patients but 
another 10% failed to meet criteria for this status solely because of PGA>1. This difference varies 
across countries: from 1.7% in India to 17.9% in Portugal. Previous studies (10, 21-25) have 
reported PGA-near-remission rates between 14% (n=236, European patients) (25) and 38% (n=309, 
patients from Coimbra, Portugal) (10). Obviously, dropping a factor from an equation, especially if 
Boolean, will lead to an increase in the proportion of observations being determined/filtered. 
However, PGA stands out from the other factors used to define remission because it: i) is much 
more subjective than other factors, and conveys information that is unrelated to inflammation, ii) 
cannot be expected to improve with immunosuppressive therapy in patients who are otherwise in 
remission, and iii) is responsible for 10 fold more cases of near-remission in the Boolean-based 
definition than each of the others factors (10.0%, versus 1.0, 0.9, and 0.7% for CRP, TJC28, SJC28 
respectively – Table 2). 
These results demonstrate a remarkable impact of PGA on the rate of patients achieving treatment 
target and suggest that 10% of RA patients overall and up to 38% of all RA patients in certain settings 
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(10) may be exposed to an overtreatment risk, if rheumatologists adhere strictly to the current 
Boolean definition of target (29).  
This is certainly worrying, unless PGA is shown to represent disease dimensions that are amenable 
to improvement by the therapies being considered, typically immunosuppressive agents. This is not 
supported by our data.  
If we consider only the patients whose treatment is recommended to increase based solely on PGA 
(PGA-near-remission), PGA shows no relationship with disease activity (Table 5), nor should it be 
expected to, given that SJC28, TJC28 and CRP (mg/dl) are all ≤1. The observation that 20% of the 
2395 patients in "strict 3v-remission" scored PGA >4, underlines this interpretation and questions 
the possibility that high PGA values in such patients may be a reflection of subclinical inflammation 
(37, 38). Although PGA has been previously attributed high face validity in overall samples of RA 
patients (18), this becomes obviously questionable in patients with low or absent signs of active 
inflammation. Confounding factors, namely the different interpretation of non-standardized 
questions (20, 39), and the impact of unrelated factors, such as comorbidities or psychological 
distress, become of paramount importance (10, 18, 40). 
Our data also demonstrate, as expected, that PGA has a positive correlation with disease activity. 
Considering the overall sample, PGA was associated with pain and function (HAQ-DI) and also, 
although to a lesser extent, with objective measures of disease activity (SJC28, CRP). Explaining 
the discrepancy observed between countries regarding the correlation between PGA and 
parameters of disease activity is beyond the scope of this paper. A multitude of factors, including 
patient education on PROs, and patient expectations are probably involved (41, 42). 
Overall, mean values of PGA were lower in patient groups with lower indices of disease activity. 
This is true at the group level (40). However, if we adopt the treat-to-target strategy, classification 
becomes individual and dichotomised (remission versus non-remission) – correlations are no longer 
relevant as even factors with a good correlation may become inadequate for classification. This is 
critical when classification has important treatment implications.  
The present study has some strengths and limitations. METEOR also incorporates data imported 
from other registries and the formulation of the PGA question presented to patients is not exactly 
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the same. Our previous research (19) suggests that PGA score varies by different formulations of 
the question. There was a significant amount of missing data (e.g. BMI, smoking status, erosions) 
that could introduce some selection bias. A sizeable proportion of PGA's variance was not explained 
by our models, in part because other variables that have been shown to impact upon PGA, such as 
fatigue and stiffness, are not available in METEOR. As health related quality of life measures are 
not included in the METEOR, we were unable to assess the correlation between PGA and quality of 
life. However, other studies have demonstrated that PGA correlates better with quality of life 
measures than with these predominantly inflammatory measures (43). There may also exist a 
selection bias derived from the fact that countries/centres that adopt a more regular metrology, and 
thus contribute to cooperative databases, are the ones with better adherence to therapeutic 
guidelines. In our analyses we have compared results across countries with quite different levels of 
income and cultural background. As main strengths, this study used a large database, from clinical 
practice and from rich and poor countries, with a diversity of cultural backgrounds. In addition, we 
used both simple and powerful statistical analyses allowing easier interpretation and implementation 
of the results in clinical practice, while providing strong evidence for practice and further research. 
Taken together, the current results and published evidence described above suggest that PGA has 
a general correlation with disease activity level, which makes it an appropriate component of indices 
used for a semi-quantitative evaluation of disease status, in a strategy aimed at making the patient 
better. They also demonstrate, however, that PGA lacks specificity and biological support around 
the cut-off points used to define treatment target and make therapeutic decisions, as demonstrated 
by a correlation of just 0.25 with DAS28CRP(3v) in patients in low-disease activity and remission 
states. A target should, by definition, be sharp and meaningful, especially when we are dealing with 
targeted immunosuppressive agents. The mean value of PGA for patients otherwise in remission 
(3.9 cm) and its distribution (37% have a PGA>4) suggest that this cannot be properly resolved by 
simply increasing the maximum acceptable value of PGA to 2 or 3, as previously suggested (27, 
28).  
This evidence supports our proposal for a dual-target strategy to manage RA (10, 29): (i) a biological 
remission target, aiming at the control of inflammation, defined by the 3v-remission concept and 
used to guide immunosuppressive therapy, and (ii) a symptom-remission target, defined by a well-
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validated and discriminative PRO, such as the Rheumatoid Arthritis Impact of Disease (RAID) score, 
to guide adjuvant therapy for the control of the disease impact factors (symptom remission). 
Achieving inflammatory remission should be seen as a strong contribution towards remission of 
disease impact, but not a guarantee. Both targets should be considered independent but obligatory 
and complementary, requiring equal attention from rheumatologists and the caring team (12). The 
full resolution of the impact of disease on patients’ lives (the ultimate objective of treatment) will 
certainly require a multidisciplinary approach involving nurses, physiotherapists, occupational 
therapists, psychologists and other health care professionals. This dual target strategy and 
separation of measures would ensure that remission is more meaningful to patients, while it is likely 
to reduce the risk of overtreatment with immunosuppressants (10, 12, 29). A study protocol within 
the scope of this proposal was recently published by a Danish research group (44), reinforcing its 
current scientific and clinical relevance.  
Nevertheless, with or without PGA, physicians should always be aware of the limitations of disease 
activity indices (such as non-inclusion of the feet, size and relevance of involved joints to the 
individual patients, active swollen joints versus cold chronic scarring) and holistically consider 
patient’s symptoms, needs, and individual circumstances (1, 2, 45).  
Further investigation will be required to verify whether the exclusion of PGA from the definition of 
remission negatively affects its long-term predictive value of important outcomes such as 
radiographic damage and physical function. This work is currently underway (46). A detailed 
examination of the potential association of PGA with subclinical inflammation in patients otherwise 
in remission is also warranted. 
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Figure 1 - PGA distribution in patients with RA in remission by DAS28-CRP(3v) and in PGA-Near-
remission.  
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ACR: American College of Rheumatology; CRP: C-reactive protein; DAS28CRP3v: disease 
activity score with 28-joint counts using C-reactive protein and 3 variables; EULAR: European 
League Against Rheumatology; PGA: Patient Global Assessment.  
Figure 1 footnote: PGA-Near-remission patients are defined as having Tender 28-Joint Counts ≤1, 
Swollen 28-Joint Counts ≤1, CRP (mg/dl) ≤1 and PGA >1/10; thus, in the graph there are no 
patients within the [0- 1] interval (those were classified in ACR/EULAR Boolean-based remission).  
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Table 1 - Summary of the clinical and demographic characteristics of the study population 
(n=27768a). 
Variable Observed 
Values b 
Missing 
% 
 
Female, n (%) 21976 (79.7)  0.7  
Age at visit (years) 52.6 (14.1)  1.8  
Country with GDP >20.000 int. Dol., n (%) 16319 (59.7)  1.5  
Disease duration, since diagnosis c (years) 4.3 (7.3)  7.6  
Year of Diagnosis ≥2000, n (%)  21430 (83.4) 7.6  
Rheumatoid factor positive, n (%) 17076 (74.7) 17.7  
ACPA positive, n (%) 11533 (71.5)  58.1  
Erosions, n (%) 7359 (54.6)  51.4  
Treatment with steroids, n (%) 10407 (37.5) 0.0  
Treatment with csDMARDs, n (%) 19556 (70.4) 0.0  
Treatment with bDMARDs, n (%) 6449 (23.2) 0.0  
Treatment with tsDMARDs, n (%) 2 (<0.1) 0.0  
TJC28 9.1 (9.0) 0.0  
SJC28 4.6 (5.3) 0.0  
CRP mg/dl 2.2 (3.0) 0.0  
PGA (0-10) 4.9 (2.6) 0.0  
DAS28-CRP(3v) 4.2 (2.6) 0.0  
SDAI remission (≤3.3), n (%) 1419 (6.4) 20.8  
CDAI remission (≤2.8), n (%) 1418 (6.4) 20.8  
Pain (0-10) 4.9 (2.6)  9.3  
HAQ-DI (0-3) 1.1 (0.7)  20.0  
ACPA: anti-citrullinated antibody; bDMARDs: Biological Disease-Modifying Antirheumatic Drugs; CDAI: Clinical Disease 
Activity Index; CRP: C-reactive protein; csDMARDs: Conventional Synthetic Disease-Modifying Antirheumatic Drugs; 
DAS28CRP: disease activity score with 28-joint counts using C-reactive protein; GDP: Gross Domestic Product; HAQ-
DI: health assessment questionnaire disability index; PGA: Patient Global Assessment; SDAI: Simplified Disease Activity 
Index; SJC28: swollen 28-joint count; TJC28: tender 28-joint count; tsDMARDs: Target Synthetic Disease-Modifying 
Antirheumatic Drugs; VAS: visual analogue scale.  
a. One visit only per patient (the first visit providing all Boolean criteria) 
b. Values are mean (SD) unless stated.  
dc This definition was chosen instead of time since the date of the onset of symptoms because the latter had 
significantly more missing data (28.2%; mean (SD) = 6.9 (8.1) years).  
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Table 2 - Impact of PGA in the various remission criteria, in the overall sample and by country 
Disease activity status 
Overall 
sample 
n=27768 
The 
Netherlands 
n=3296 
Italy 
n=4156 
Portugal 
n=4373 
India 
n=8936 
Other 
countries 
n=7007 
ACR/EULAR Boolean-based, n (%) 
4v-Remission a 
PGA-near-remission b 
Non-remission c 
 
1605 (5.8) 
2776 (10.0) 
23387 (84.2) 
 
202 (6.1) 
453 (13.7) 
2641 (80.2) 
 
243 (5.8) 
293 (7.1) 
3620 (87.1) 
 
395 (9.0) 
784 (17.9) 
3194 (73.1) 
 
5 (0.1) 
151 (1.7) 
8780 (98.2) 
 
760 (10.8) 
1095 (15.6) 
5152 (73.6) 
(Proposed) 3v-Remission d 4381 (15.8) 655 (19.8) 536 (12.9) 1179 (26.9) 156 (1.8) 1855 (26.4) 
Near-Remission e only, n (%) 
due to PGA 
due to CRP 
due to TJC28 
due to SJC28 
 
2776 (79.7) 
271 (7.8) 
249 (7.2) 
185 (5.3) 
 
453 (74.1) 
57 (9.3) 
63 (10.3) 
38 (6.2) 
 
293 (78.3) 
31 (8.3) 
32 (8.6) 
18 (4.8) 
 
784 (82.4) 
82 (8.6) 
47 (4.9) 
39 (4.1) 
 
151 (91.5) 
5 (3.0) 
8 (4.8) 
1 (0.6) 
 
1095 (79.4) 
96 (7.0) 
99 (7.2) 
89 (6.5) 
DAS28CRP3v f, n (%)  
Remission (<2.4) 
Low (≥2.4 ≤2.9) 
 
4629 (16.7) 
2258 (8.1) 
 
601 (18.2) 
434 (13.2) 
 
561 (13.5) 
313 (7.5) 
 
1269 (29.0) 
514 (11.8) 
 
142 (1.6) 
210 (2.4) 
 
2056 (29.3) 
787 (11.3) 
DAS28CRP4v f, n (%) 
Remission (<2.4) 
Low (≥2.4 ≤2.9) 
 
4131 (14.9) 
1957 (7.0) 
 
551 (16.7) 
395 (12.0) 
 
503 (12.1) 
236 (5.7) 
 
1130 (25.8) 
468 (10.7) 
 
96 (1.1) 
150 (1.7) 
 
1851 (26.4) 
708 (10.1) 
Differences between 3v and 4v 
definitions, % 
for DAS28CRP remission / low 
for ACR/EULAR Boolean remission 
 
 
1.8% / 2.9% 
10.0% 
 
 
1.5% / 2.7% 
13.7% 
 
 
1.4% / 3.2% 
7.1% 
 
 
3.2% / 4.3% 
17.9% 
 
 
0.5% / 1.2% 
1.7% 
 
 
2.9% / 4.1% 
15.6% 
ACR: America College of Rheumatology; DAS28CRP3v: disease activity score with 28-joint counts using C-reactive 
protein and 3 variables; DAS28CRP4v: disease activity score with 28-joint counts using C-reactive protein and 4 
variables; EULAR: European League Against Rheumatology; SJC28: swollen 28-joint count; TJC28: tender 28-joint 
count; CRP: C-reactive protein; PGA: Patient Global Assessment 
a. 4v-Remission = TJC28, SJC28, CRP mg/dl, and PGA all ≤1   
b. PGA-near-remission = TJC28, SJC28, and CRP mg/dl all≤1; PGA>1   
c. Non-remission = two or more out of the four criterion (TJC28, SJC28, CRP, or PGA) are >1 
d. TJC28, SJC28, and CRP mg/dl all≤1; PGA not considered. It equates to merging "4v-remission" and "PGA-near-
remission" disease states  
e. Near-remission = only one out of the four criterion (TJC28, SJC28, CRP, or PGA) are >1 
f. The cut-offs proposed by Fleischmann et al. [29] were used 
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Table 3 – Mean values of PGA across disease activity states 
Disease activity status 
Mean (SD) PGA, in cm 
Overall 
sample 
n=27768 
The 
Netherlands 
n=3296 
Italy 
n=4156 
Portugal 
n=4373 
India 
n=8936 
Other 
countries 
n=7007 
ACR/EULAR Boolean-based PGA-near 
remission, n (%) 
Remission a 
PG-Near-remission b 
Non-remission c  
 
 
0.4 (0.4) 
3.9 (2.0) 
5.3 (2.4) 
 
 
0.4 (0.4) 
3.8 (1.9) 
4.1 (2.6) 
 
 
0.3 (0.4) 
4.2 (2.2) 
6.1 (2.5) 
 
 
0.4 (0.4) 
3.9 (1.9) 
5.1 (2.6) 
 
 
0.0 (0.0) 
3.8 (1.6) 
5.5 (1.8) 
 
 
0.4 (0.4) 
3.8 (2.0) 
5.2 (2.7) 
DAS28CRP3v d, n (%) 
Remission (<2.4) 
Low (≤2.9) 
Moderate (≤4.6) 
High (>4.6) 
 
2.5 (2.3) 
3.7 (2.4) 
4.9 (2.3) 
6.2 (2.1) 
 
2.6 (2.2) 
3.2 (2.3) 
4.0 (2.5) 
4.8 (2.6) 
 
2.4 (2.4) 
4.0 (2.6) 
5.7 (2.2) 
7.2 (2.1) 
 
2.7 (2.3) 
3.6 (2.4) 
4.9 (2.4) 
6.5 (2.2) 
 
3.7 (1.6) 
4.2 (1.8) 
4.9 (1.8) 
5.9 (1.7) 
 
2.4 (2.3) 
3.7 (2.5) 
4.9 (2.4) 
6.8 (2.2) 
ACR: America College of Rheumatology; DAS28CRP3v: disease activity score with 28-joint counts using C-reactive 
protein and 3 variables; EULAR: European League Against Rheumatology; PGA: Patient Global Assessment 
a. Remission = TJC28, SJC28, CRP mg/dl, and PGA all ≤1   
b. PGA-Near-remission = TJC28, SJC28, CRP mg/dl, are all ≤1, and PGA >1  
c. Non-remission = TJC28 or SJC28 or CRP mg/dl >1, irrespective of PGA value 
d. The cut-off proposed by Fleischmann et al. [29] were used 
 
 
 
Table 4 - Pearson's Coefficient correlations between PGA and inflammatory and disease impact 
measures by country and by disease activity status. 
  PGA correlation* 
 TJC28 SJC28 
CRP 
mg/dl 
DAS28-
CRP3v 
Pain 
(0-10)a 
HAQ-DIb 
All countries (n=27768) 0.43 0.36 0.23 0.51 0.75 0.52 
The Netherlands (n=3296) 0.27 0.17 0.13 0.30 0.57 0.39 
Italy (n=4156) 0.51 0.42 0.18 0.58 0.86 0.57 
Portugal (n=4373) 0.48 0.40 0.21 0.54 0.86 0.57 
India (n=8936) 0.30 0.20 0.20 0.34 0.65 0.50 
Other countries (n=7007) 0.52 0.43 0.24 0.59 0.74 0.56 
CRP: C-reactive protein; HAQ-DI: Health Assessment Questionnaire Disability Index; PGA: Patient Global Assessment; 
SJC28: swollen 28-joint count; TJC28: tender 28-joint count. 
a. Percentage of missing data for Pain was 9.3% (Overall sample), 18.6% (The Netherlands), 4.3% (Italy), 21.4% (Portugal), <0.1% 
(India) and 12.1% (Other countries). 
b. Percentage of missing data for HAQ was 19.9% (Overall sample), 49.0% (The Netherlands), 13.8% (Italy), 21.6% (Portugal), 6.9% 
(India) and 25.5% (Other countries). 
* p-values were <0.001 in all instances 
Correlations ≥0.50 are in bold. 
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Table 5 - Multivariable linear regression analysis to explain PGAa (n=20719). 
variable 
Unstandardized 
β 
β 
 95% Confidence interval for β Adjusted R-
Square 
p-value 
p-value Lower bound Upper bound 
Constant 1.232  <0.001 1.181 1.284 
0.573 <0.001 
TJC28 0.030 0.111 <0.001 0.027 0.033 
SJC28 0.014 0.030 <0.001 0.009 0.19 
CRP mg/dl 0.027 0.034 <0.001 0.019 0.035 
Pain 0.058 0.591 <0.001 0.057 0.059 
HAQ-DI 0.548 0.156 <0.001 0.510 0.585 
CRP: C-reactive protein; HAQ-DI: Health Assessment Questionnaire Disability Index; PGA: Patient Global Assessment; 
SJC28: swollen 28-joint count; TJC28: tender 28-joint count.  
a. Using Enter's method and TJC28, SJC28, CRP, Pain and HAQ-DI as independent variables. 
 
